4.1 Article

Atopic Dermatitis and Keratoconjunctivitis

Journal

Publisher

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.iac.2010.06.004

Keywords

Atopic dermatitis; Atopic keratoconjunctivitis; Ocular allergy; Blepharoconjunctivitis; Keratoconus

Funding

  1. Schering-Plough
  2. Glaxo-Smith-Kline
  3. Merck
  4. Otsuka
  5. Novartis
  6. Sanofi-Aventis
  7. Genentech
  8. UCB-Pharma
  9. Alcon
  10. Meda
  11. Inspire
  12. Santen
  13. Allergan
  14. ISTA
  15. SARCode
  16. Bausch and Lomb
  17. Vistakon
  18. ViroPharm
  19. Dyax
  20. Jerini
  21. Ocusense (Tear Lab)
  22. Rutgers University Press
  23. Astellas

Ask authors/readers for more resources

Atopic dermatitis, a chronic disease seen by allergist-immunologists, has both dermatologic and ocular manifestations. The ocular component is often disproportionately higher than the dermatologic disease. Even if skin abnormalities seem well controlled, these patients require ophthalmic evaluation. Atopic keratoconjunctivitis in atopic dermatitis patients is characterized by acute exacerbations and requires maintenance therapy for long-term control. Future studies will continue to emphasize the use of steroid-sparing, immunomodulating agents that have the potential to provide long-lasting anti-inflammatory control with a more favorable side-effect profile.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available